VTEX Q2 2026: Growth Still Stuck as Take-Rate Slides Further

What happened

VTEX's Q2 2026 results fell short of the re-acceleration needed to reverse the narrative, with FX-neutral subscription growth hovering around 5% and take-rate slipping to 1.18%, down from 1.21% a year earlier. Brazil same-store sales remained in low-single digits, and management acknowledged that the region’s recovery is still unpredictable, offering no clear stabilization signal. While Rest-of-World revenue mix ticked up modestly to 12%, the lack of meaningful geographic diversification keeps the company exposed to LatAm headwinds. Cost discipline held non-GAAP operating margins in the low-20s, and the company repurchased additional shares, but the core growth engine continues to lose traction. The call’s cautious tone underscores that the 'wait-for-evidence' thesis is still firmly in place.

Implication

The Q2 print reinforces that VTEX’s monetization model remains under pressure, with take-rate declines persisting despite easier GMV comparisons, making the path to $5+ per share distant. Near-term, the stock may test the $2.75 attractive entry level, but without growth re-ignition, any bounce is likely tactical rather than the start of a sustained re-rating. The gradual international mix shift offers a silver lining, but it is too incremental to offset Brazil’s outsized influence on results over the next 12 months. Management’s continued buybacks provide a floor, but at current valuations of over 30x earnings, the margin of safety is thin. We maintain a WAIT rating until clear evidence of re-acceleration emerges, with downside risk to $2.10 in a bearish LatAm macro scenario.

Thesis delta

The Q2 results confirm that the hoped-for second-half 2026 re-acceleration is not materializing, with take-rate continuing to decline and no sign of a Brazil trough. The international expansion narrative is still early-stage and lacks the scale to de-risk the investment case. As a result, the probability of the bull scenario ($5.20) has decreased, while the bear case ($2.10) looks more plausible if macro conditions worsen.